Fecal microbiota transplantation restores gut microbiota diversity in children with active Crohn's disease: a prospective trial

From BugSigDB
Needs review
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Zou B, Liu S, Dong C, Shen H, Lv Y, He J, Li X, Ruan M, Huang Z, Shu S
Journal
Journal of translational medicine
Year
2025
Keywords:
Children, Core functional genera, Crohn’s disease, Efficacy and safety, Oral fecal microbiota capsules
BACKGROUND: Clinical data on oral fecal microbiota transplantation (FMT), a promising therapy for Crohn's disease (CD), are limited. Herein, we determined the short-term safety and feasibility of FMT for pediatric patients with active CD. METHODS: In this open-label, parallel-group, single-center prospective trial, patients with active CD were treated with oral FMT capsules combined with partial enteral nutrition (PEN) (80%). The control group comprised pediatric patients with active CD treated with PEN (80%) and immunosuppressants. Thirty-three patients (11.6 ± 1.82 years)-17 in the capsule and 16 in the control groups-were analyzed. Data regarding the adverse events, clinical reactions, intestinal microbiome composition, and biomarker parameters were collected and compared post-treatment. RESULTS: At week 10, the clinical and endoscopic remission rates did not differ between the two groups. By week 10, the mean fecal calprotectin level, C-reactive protein level, erythrocyte sedimentation rate, simple endoscopic score for CD, and pediatric CD activity index decreased significantly in the capsule group (all P < 0.05). The main adverse event was mild-to-moderate constipation. Core functional genera, Agathobacter, Akkermansia, Roseburia, Blautia, Subdoligranulum, and Faecalibacterium, were lacking pre-treatment. Post-treatment, the implantation rates of these core functional genera increased significantly, which positively correlated with the anti-inflammatory factor, interleukin (IL)-10, and negatively correlated with the pro-inflammatory factor, IL-6. The combination of these six functional genera distinguished healthy children from those with CD (area under the curve = 0.96). CONCLUSIONS: Oral FMT capsules combined with PEN (80%) could be an effective therapy for children with active CD. The six core functional genera identified here may be candidate biomarkers for identifying children with CD. TRIAL REGISTRATION: ClinicalTrials.gov, retrospectively registered, ID# NCT05321758, NCT05321745, date of registration: 2022-04-04.

Experiment 1


Needs review

Curated date: 2025/03/24

Curator: EniolaAde

Revision editor(s): EniolaAde

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Crohn's disease Colitis, Granulomatous,CROHN DIS,Crohn Disease,Crohn disease,Crohn's associated gastritis,Crohn's disease,Crohn's disease of colon,Crohn's disease of large bowel,CROHNS DIS,Crohns Disease,Enteritis, Granulomatous,Enteritis, Regional,Gastritis Associated with Crohn Disease,Gastritis Associated with Crohn's Disease,granulomatous colitis,Ileitis, Regional,Ileitis, Terminal,Ileocolitis,pediatric Crohn's disease,regional enteritis,crohn disease,crohn's disease
Group 0 name Corresponds to the control (unexposed) group for case-control studies
healthy group
Group 1 name Corresponds to the case (exposed) group for case-control studies
crohn's disease
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
patients with Crohn's disease
Group 0 sample size Number of subjects in the control (unexposed) group
16
Group 1 sample size Number of subjects in the case (exposed) group
42

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Spearman Correlation
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
3.5

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
decreased
Chao1 Abundance-based estimator of species richness
decreased
Simpson Estimator of species richness and species evenness: more weight on species evenness
decreased
Richness Number of species
decreased

Signature 1

Needs review

Curated date: 2025/03/24

Curator: EniolaAde

Revision editor(s): EniolaAde

Source: Within-text result of "Improvement in microbial dysbiosis following oral FMT administration"

Description: relative abundance in patients with Crohns disease vs healthy donor control

Abundance in Group 1: increased abundance in crohn's disease

NCBI Quality ControlLinks
Pseudomonadota

Revision editor(s): EniolaAde

Signature 2

Needs review

Curated date: 2025/03/24

Curator: EniolaAde

Revision editor(s): EniolaAde

Source: Within-text result of "Improvement in microbial dysbiosis following oral FMT administration"

Description: relative abundance in patients with crohns disease and healthy donor control

Abundance in Group 1: decreased abundance in crohn's disease

NCBI Quality ControlLinks
Bacteroidia

Revision editor(s): EniolaAde

Experiment 2


Needs review

Curated date: 2025/03/29

Curator: EniolaAde

Revision editor(s): EniolaAde

Differences from previous experiment shown

Subjects

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Response to transplant Response to transplant,response to transplant
Group 1 name Corresponds to the case (exposed) group for case-control studies
crohn's disease (FMT0W)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
patients with Crohn's disease before fecal microbiota transplantation treatment (FMT0W)
Group 1 sample size Number of subjects in the case (exposed) group
17

Lab analysis

Statistical Analysis

Statistical test
LEfSe

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
decreased
Chao1 Abundance-based estimator of species richness
decreased
Simpson Estimator of species richness and species evenness: more weight on species evenness
increased
Richness Number of species
decreased

Signature 1

Needs review

Curated date: 2025/03/29

Curator: EniolaAde

Revision editor(s): EniolaAde

Source: supplementary figure 3

Description: LEfSe of the different genera in healthy donor control and patients with crohns disease before FMT

Abundance in Group 1: decreased abundance in crohn's disease (FMT0W)

NCBI Quality ControlLinks
Agathobacter
Anaerobutyricum hallii
Anaerostipes
Bacteroidales
Bacteroidia
Bacteroidota
Blautia
Clostridia
Dialister
Eubacteriales
Faecalibacterium
Negativicutes
Oscillospiraceae
Roseburia
Ruminococcus
Streptococcaceae
Streptococcus
Subdoligranulum
Sutterellaceae

Revision editor(s): EniolaAde

Signature 2

Needs review

Curated date: 2025/03/29

Curator: EniolaAde

Revision editor(s): EniolaAde

Source: supplementary figure 3

Description: LEfSe of the different genera in healthy donor control and patients with crohns disease before FMT

Abundance in Group 1: increased abundance in crohn's disease (FMT0W)

NCBI Quality ControlLinks
Bifidobacteriaceae
Bifidobacteriales
Bifidobacterium
Coriobacteriaceae
Enterococcaceae
Enterococcus
Morganellaceae

Revision editor(s): EniolaAde

Experiment 3


Needs review

Curated date: 2025/04/09

Curator: EniolaAde

Revision editor(s): EniolaAde

Differences from previous experiment shown

Subjects

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Crohn's disease Colitis, Granulomatous,CROHN DIS,Crohn Disease,Crohn disease,Crohn's associated gastritis,Crohn's disease,Crohn's disease of colon,Crohn's disease of large bowel,CROHNS DIS,Crohns Disease,Enteritis, Granulomatous,Enteritis, Regional,Gastritis Associated with Crohn Disease,Gastritis Associated with Crohn's Disease,granulomatous colitis,Ileitis, Regional,Ileitis, Terminal,Ileocolitis,pediatric Crohn's disease,regional enteritis,crohn disease,crohn's disease
Group 0 name Corresponds to the control (unexposed) group for case-control studies
healthy donor group
Group 1 name Corresponds to the case (exposed) group for case-control studies
FMT0W group
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
patients with Crohn's disease before FMT treatment

Lab analysis

Statistical Analysis

Statistical test
Kruskall-Wallis

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
decreased
Chao1 Abundance-based estimator of species richness
decreased
Simpson Estimator of species richness and species evenness: more weight on species evenness
decreased
Richness Number of species
decreased

Signature 1

Needs review

Curated date: 2025/04/09

Curator: EniolaAde

Revision editor(s): EniolaAde

Source: sup fig 4

Description: relative abundance of bacteria between healthy donor group and pre-FMT

Abundance in Group 1: decreased abundance in FMT0W group

NCBI Quality ControlLinks
Agathobacter
Akkermansia
Anaerostipes
Blautia
Faecalibacterium
Roseburia
Streptococcus
Subdoligranulum

Revision editor(s): EniolaAde

Signature 2

Needs review

Curated date: 2025/04/09

Curator: EniolaAde

Revision editor(s): EniolaAde

Source: sup fig 4

Description: relative proportion of bacteria between healthy donor group and pre-FMT

Abundance in Group 1: increased abundance in FMT0W group

NCBI Quality ControlLinks
Clostridioides
Enterobacter
Enterococcus
Escherichia/Shigella sp.

Revision editor(s): EniolaAde

Experiment 4


Needs review

Curated date: 2025/04/09

Curator: EniolaAde

Revision editor(s): EniolaAde

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
FMT0W
Group 1 name Corresponds to the case (exposed) group for case-control studies
FMT5W
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
patients given fecal microbiota transplantation treatment after five weeks
Group 0 sample size Number of subjects in the control (unexposed) group
17
Group 1 sample size Number of subjects in the case (exposed) group
8

Lab analysis

Statistical Analysis

Statistical test
Mann-Whitney (Wilcoxon)

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged
Chao1 Abundance-based estimator of species richness
increased
Simpson Estimator of species richness and species evenness: more weight on species evenness
unchanged
Richness Number of species
increased

Signature 1

Needs review

Curated date: 2025/04/09

Curator: EniolaAde

Revision editor(s): EniolaAde

Source: Figure 6A

Description: relative abundance genera between FMT0W and FMT5W

Abundance in Group 1: increased abundance in FMT5W

NCBI Quality ControlLinks
Agathobacter
Subdoligranulum
Blautia

Revision editor(s): EniolaAde

Experiment 5


Needs review

Curated date: 2025/04/09

Curator: EniolaAde

Revision editor(s): EniolaAde

Differences from previous experiment shown

Subjects

Group 1 name Corresponds to the case (exposed) group for case-control studies
FMT10W
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
patients given FMT treatment after ten weeks
Group 1 sample size Number of subjects in the case (exposed) group
17

Lab analysis

Statistical Analysis

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged
Chao1 Abundance-based estimator of species richness
increased
Simpson Estimator of species richness and species evenness: more weight on species evenness
unchanged
Richness Number of species
increased

Signature 1

Needs review

Curated date: 2025/04/09

Curator: EniolaAde

Revision editor(s): EniolaAde

Source: Figure 6A

Description: relative abundance between FMT0W and FMT10W

Abundance in Group 1: increased abundance in FMT10W

NCBI Quality ControlLinks
Agathobacter
Akkermansia
Blautia
Faecalibacterium
Roseburia
Subdoligranulum

Revision editor(s): EniolaAde

Experiment 6


Needs review

Curated date: 2025/04/10

Curator: EniolaAde

Revision editor(s): EniolaAde

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
healthy donor group
Group 1 name Corresponds to the case (exposed) group for case-control studies
FMT0W
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
patients with crohns disease before FMT treatment
Group 0 sample size Number of subjects in the control (unexposed) group
16

Lab analysis

Statistical Analysis

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged
Chao1 Abundance-based estimator of species richness
increased
Simpson Estimator of species richness and species evenness: more weight on species evenness
unchanged
Richness Number of species
increased

Experiment 7


Needs review

Curated date: 2025/04/10

Curator: EniolaAde

Revision editor(s): EniolaAde

Differences from previous experiment shown

Subjects

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Response to transplant Response to transplant,response to transplant
Group 0 name Corresponds to the control (unexposed) group for case-control studies
FMT0W
Group 1 name Corresponds to the case (exposed) group for case-control studies
FMT10W
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
patients given FMT treatment after 10 weeks
Group 0 sample size Number of subjects in the control (unexposed) group
17

Lab analysis

Statistical Analysis

Statistical test
Kruskall-Wallis

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
decreased
Chao1 Abundance-based estimator of species richness
decreased
Simpson Estimator of species richness and species evenness: more weight on species evenness
decreased
Richness Number of species
decreased